(Q37355807)

19 August 2017

1 reference

title

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review (English)

1 reference

19 August 2017

0 references

1 reference

Virgínia Fernandes Moça Trevisani

1

1 reference

19 August 2017

Rachel Riera

2

1 reference

19 August 2017

Aline Mizusaki Imoto

3

1 reference

19 August 2017

Humberto Saconato

4

1 reference

19 August 2017

Alvaro Nagib Atallah

5

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Sao Paulo Medical Journal

19 August 2017

published in

1 reference

19 August 2017

volume

126

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

279-284

1 reference

Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Diagnosis of osteoporosis and assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Impact of hip and vertebral fractures on quality-adjusted life years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Late Physical and Functional Effects of Osteoporotic Fracture in Women: The Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Perspective. How many women have osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802008000500007

10.1590/S1516-31802008000500007

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference